BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 22415233)

  • 1. The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer.
    Popple A; Durrant LG; Spendlove I; Rolland P; Scott IV; Deen S; Ramage JM
    Br J Cancer; 2012 Mar; 106(7):1306-13. PubMed ID: 22415233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue Expression and Prognostic Role of CXCL12 and CXCR4 in High-grade Serous Ovarian Carcinoma.
    Lim H; Kim SI; Kim EN; Lee M; Lee C; Kim JW; Chung HH
    Anticancer Res; 2023 Jul; 43(7):3331-3340. PubMed ID: 37351997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemokine axes CXCL12/CXCR4 and CXCL16/CXCR6 correlate with lymph node metastasis in epithelial ovarian carcinoma.
    Guo L; Cui ZM; Zhang J; Huang Y
    Chin J Cancer; 2011 May; 30(5):336-43. PubMed ID: 21527066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression.
    Jiang YP; Wu XH; Shi B; Wu WX; Yin GR
    Gynecol Oncol; 2006 Oct; 103(1):226-33. PubMed ID: 16631235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and biological significance of CXCL12 and CXCR4 expression in adult testes and germ cell tumours of adults and adolescents.
    Gilbert DC; Chandler I; McIntyre A; Goddard NC; Gabe R; Huddart RA; Shipley J
    J Pathol; 2009 Jan; 217(1):94-102. PubMed ID: 18839394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro.
    Liu Y; Ren CC; Yang L; Xu YM; Chen YN
    J Cell Physiol; 2019 Apr; 234(4):3897-3909. PubMed ID: 30191987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival.
    Mirisola V; Zuccarino A; Bachmeier BE; Sormani MP; Falter J; Nerlich A; Pfeffer U
    Eur J Cancer; 2009 Sep; 45(14):2579-87. PubMed ID: 19646861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relationship between chemokine axis CXCL12-CXCR4 and epithelial ovarian cancer].
    Guo Q; Wu XH; Lü YP; Yang B; Xu F; Zhang SJ
    Zhonghua Yi Xue Za Zhi; 2013 Jun; 93(21):1677-80. PubMed ID: 24125682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer.
    Zheng N; Liu W; Chen J; Li B; Liu J; Wang J; Gao Y; Shao J; Jia L
    Mol Carcinog; 2019 Jan; 58(1):144-155. PubMed ID: 30259564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic significance and impact of the CXCR4-CXCR7-CXCL12 axis in primary cutaneous melanoma.
    McConnell AT; Ellis R; Pathy B; Plummer R; Lovat PE; O'Boyle G
    Br J Dermatol; 2016 Dec; 175(6):1210-1220. PubMed ID: 27167239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients.
    D'Alterio C; Avallone A; Tatangelo F; Delrio P; Pecori B; Cella L; Pelella A; D'Armiento FP; Carlomagno C; Bianco F; Silvestro L; Pacelli R; Napolitano M; Iaffaioli RV; Scala S
    Int J Cancer; 2014 Jul; 135(2):379-90. PubMed ID: 24375277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between CXCR4/CXCR7/CXCL12 chemokine axis expression and prognosis in lymph-node-positive lung cancer patients.
    Katsura M; Shoji F; Okamoto T; Shimamatsu S; Hirai F; Toyokawa G; Morodomi Y; Tagawa T; Oda Y; Maehara Y
    Cancer Sci; 2018 Jan; 109(1):154-165. PubMed ID: 29032612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of CXCL12, CXCR4, and CXCR7 in patients with breast cancer.
    Wu W; Qian L; Chen X; Ding B
    Int J Clin Exp Pathol; 2015; 8(10):13217-24. PubMed ID: 26722521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCR4, CXCL12 and the relative CXCL12-CXCR4 expression as prognostic factors in colon cancer.
    Stanisavljević L; Aßmus J; Storli KE; Leh SM; Dahl O; Myklebust MP
    Tumour Biol; 2016 Jun; 37(6):7441-52. PubMed ID: 26678887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging CXCL12-CXCR4 signaling in ovarian cancer therapy.
    Salomonnson E; Stacer AC; Ehrlich A; Luker KE; Luker GD
    PLoS One; 2013; 8(1):e51500. PubMed ID: 23372646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4.
    Ray P; Lewin SA; Mihalko LA; Schmidt BT; Luker KE; Luker GD
    Neoplasia; 2011 Dec; 13(12):1152-61. PubMed ID: 22241961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemokine receptor CCR7 expression predicts poor outcome in uveal melanoma and relates to liver metastasis whereas expression of CXCR4 is not of clinical relevance.
    van den Bosch T; Koopmans AE; Vaarwater J; van den Berg M; de Klein A; Verdijk RM
    Invest Ophthalmol Vis Sci; 2013 Nov; 54(12):7354-61. PubMed ID: 24052640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow.
    Shakir M; Tang D; Zeh HJ; Tang SW; Anderson CJ; Bahary N; Lotze MT
    Pancreas; 2015 May; 44(4):528-34. PubMed ID: 25872129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stromal CXCR4 and CXCL12 expression is associated with distant recurrence and poor prognosis in rectal cancer after chemoradiotherapy.
    Saigusa S; Toiyama Y; Tanaka K; Yokoe T; Okugawa Y; Kawamoto A; Yasuda H; Inoue Y; Miki C; Kusunoki M
    Ann Surg Oncol; 2010 Aug; 17(8):2051-8. PubMed ID: 20177796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear expression of chemokine receptor CXCR4 indicates poorer prognosis in gastric cancer.
    Masuda T; Nakashima Y; Ando K; Yoshinaga K; Saeki H; Oki E; Morita M; Oda Y; Maehara Y
    Anticancer Res; 2014 Nov; 34(11):6397-403. PubMed ID: 25368239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.